US Stock MarketDetailed Quotes

SLRN Acelyrin

Watchlist
  • 2.140
  • -0.060-2.73%
Close Jan 8 16:00 ET
  • 2.120
  • -0.020-0.93%
Post 19:45 ET
214.70MMarket Cap-0.81P/E (TTM)

Acelyrin Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Acelyrin Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 5 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 0.000--
--2024/Q4-- / 0.000--
Nov 13, 20242024/Q30.000 / 0.000--
Aug 13, 20242024/Q20.000 / 0.000--
May 13, 20242024/Q10.000 / 0.000--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 0.000--
--2024/Q4-- / 0.000--
Nov 13, 20242024/Q30.000 / 0.000--
Aug 13, 20242024/Q20.000 / 0.000--
May 13, 20242024/Q10.000 / 0.000--

Unlock Free Earnings Estimates

Acelyrin Earnings Reports

  • Acelyrin | 10-Q: Q3 2024 Earnings Report

    Nov 13, 2024 16:10 ET

  • Acelyrin | 8-K: ACELYRIN, INC. Reports Third Quarter 2024 Financial Results and Recent Highlights

    Nov 13, 2024 16:09 ET

  • Acelyrin | 10-Q: Q2 2024 Earnings Report

    Aug 13, 2024 16:24 ET

  • Acelyrin | 8-K: ACELYRIN, INC. Announces Positive Phase 3 Data for Izokibep in Hidradenitis Suppurativa; Focuses Strategy on Lonigutamab and Reports Second Quarter 2024 Financial Results

    Aug 13, 2024 16:18 ET

    • Read more

    Analysis

    Analyst Rating

    Updated: Jan 9, 2025

    Buy

    • Buy

      60.00%

    • Hold

      40.00%

    • Sell

      0.00%

    Price Target

    No Data

    Heat List
    US
    Overall
    Symbol
    Price
    % Chg

    No Data